Histopathologic, molecular, and clinical associations of fusion-positive gastrointestinal carcinomas
Bennett A Caughey, Sean T Bannon, Chloe Simms, Haley Barnes, Leontios Pappas, Valentina Nardi, Dora Dias-Santagata, A John Iafrate, Ryan B Corcoran, Charlotte I Wang · 2026
Read Histopathologic, molecular, and clinical associations of fusion-positive gastrointestinal carcinomas by Bennett A Caughey, Sean T Bannon, Chloe Simms, Haley Barnes, Leontios Pappas, Valentina Nardi, Dora Dias-Santagata, A John Iafrate, Ryan B Corcoran, Charlotte I Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13350599.txt.
Description
Bennett A Caughey and colleagues analysed in 2026 fusion-positive gastrointestinal cancers, examining histopathologic, molecular, and clinical associations from routine RNA-based fusion testing. Comprehensive genomic profiling guides care, yet outside biliary tract cancers, actionable fusions are uncommon and the value of routine RNA fusion testing in gut cancers was not well established.
Among 2,300 patients tested at a single centre, 139, about six percent, had a detected fusion, with biliary cancers showing the highest rates. Tumours with fusions were characterised for molecular and tissue patterns, and RSPO2/3 fusions in lower gut cancers were examined for survival and targeted therapy benefit. The study clarifies when routine fusion testing changes treatment for gastrointestinal cancers.
Catalog record
| CREATOR | Bennett A Caughey, Sean T Bannon, Chloe Simms, Haley Barnes, Leontios Pappas, Valentina Nardi, Dora Dias-Santagata, A John Iafrate, Ryan B Corcoran, Charlotte I Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |